Background. Although renal transplant recipients (RTR) have been included as patients with chronic kidney disease (CKD) by the Kidney Disease Outcome Quality Initiative (K/DOQI), there are very few studies looking at CKD complications among paediatric RTR. Methods. CKD parameters of paediatric RTR with at least 1 year post-transplant follow-up were retrospectively reviewed as per K/DOQI criteria. Results. The study population included 129 RTR aged 2.7-20 (median 13.9) years, of which 67% were male and 87% Caucasian with follow-up between 1 and 14.8 (median 3.8) years. Sixty-six per cent of RTR were in either CKD Stage 3 (70) or 4 (15). A high incidence of CKD complications was identified (albuminuria 60%, anaemia 50%, acidosis 30%, hyperparathyroidism 20%, hypoalbuminaemia 16%, hyperphosphataemia 12% and hypocalcaemia 3%). Hypertension (defined as systolic blood pressure greater than 95th percentile for age and height or on any anti-hypertensive medication) was found in 53% (n = 68) of the study population, out of which 7% (n = 5) was having uncontrolled hypertension with systolic blood pressure greater than 95th percentile despite being on anti-hypertensive medication. There was an increase in complications (P = 0.0001) as well as use of CKD medications (erythropoietin-stimulating agent, sodium bicarbonate, 1-alfacalcidol and phosphate binders) across the CKD stages in RTR (P = 0.001). Conclusion. The study confirmed a high prevalence of CKD with its related complications along with increase in frequency of complications across the stages of CKD among paediatric RTR. Further multi-centre prospective studies are required to substantiate our findings and to explore whether early identification and intervention can improve renal allograft outcome.
Introduction
The inclusion of renal transplant recipients (RTR) in the Kidney Disease Outcome Quality Initiative (K/DOQI) classification of chronic kidney disease (CKD) was recently re-affirmed in the position statement from Kidney Disease Improving Global Outcome (KDIGO), which stated that all RTR should be classified as CKD with suffix (T) irrespective of glomerular filtration rate (GFR) or presence or absence of markers of kidney damage [1, 2] . Although the relevance of K/DOQI classification for RTR has been examined in a number of adult studies [3] [4] [5] [6] [7] , there are very few paediatric studies [8, 9] . This study was performed to prove the hypothesis that, similar to adults, implementing K/DOQI recommendations among paediatric RTR will identify significant CKDrelated complications.
Materials and methods

Study design and setting
This was a retrospective cross-sectional study of paediatric RTR at Great Ormond Street Hospital for Children NHS Trust, London. Ethical approval was obtained for this study from the Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust Research Ethics Committee.
Participants
Participants were all RTR under our transplant clinic with at least 1 year post-transplant follow-up.
Data collections and variables of interest
Medical records were reviewed to obtain demographic characteristics, primary cause of end-stage renal failure (ESRF), ESRF modalities, age at transplantation, donor type (living or deceased), post-transplant duration, immunosuppressive regimen and current medications. Clinical data extracted included anthropometric measurements [weight and height at last clinic visit, which were used to calculate height standard deviation score (SDS) and body mass index (BMI) SDS] and mean of three Doppler systolic blood pressure (SBP) measurements, which were classified according to The Fourth US Task Force on hypertension recommendations [10] . For laboratory data, the three most recent values over the preceding 6 months were recorded and the mean reported for haemoglobin (Hb), ferritin, creatinine, bicarbonate, albumin, total and corrected calcium (corrected for serum albumin), phosphate, calcium phosphate product, parathyroid hormone (PTH), urine albumin:creatinine ratios (UAC) and trough calcineurin inhibitor (tacrolimus) levels.
Prevalence of CKD was classified according to their estimated GFR (eGFR) using the abbreviated Schwartz formula as per K/DOQI guidelines [1, 2, 11] . The averages of the three most recent serum creatinine, height at last clinic visit and 'k' specific for our laboratory were used to calculate the eGFR [12, 13] . The complications of CKD were ascertained as per K/DOQI guideline (Table 1) [14, 15] . PTH data were also analysed as per normal range for our laboratory (0.7 to 5.6 pmol/L) irrespective of CKD staging. We defined short stature if the height was <2 SDS and obesity if BMI was >2 SDS.
Statistical analysis
Descriptive statistics were expressed as median and range or mean and standard deviation. One-way analysis of variance (ANOVA) F test (for parametric data) or Kruskal-Wallis test (for non-parametric data) was used to compare continuous variables and the chi-square test to compare proportions between groups. Trends across stages for continuous variables were analysed by Cuzick trend test and for proportions by chi-square test for trend. A P value of less than 0.05 was considered significant. Statistical analysis was performed with StatsDirect package Version 1.9.8.
Results
Participants
One hundred and fifty paediatric RTR were followed up at our hospital of, which 129 met our inclusion criteria. Twenty-one children were excluded (15 with follow-up less than a year and six failed transplants on dialysis).
Descriptive data
The study population (67% male) had a follow-up of 1-14.8 (median 3.8) years and were aged 1.3-16.7 (median 7.8) years and 2.7-20 (median 13.9) years at transplantation and follow-up, respectively (Table 2) .
Sixty (47%) RTR had living related donors with 118 (91%), 10 (8%) and one (1%) receiving their first, second and third renal transplants, respectively.
Thirty-nine (30%) RTR received pre-emptive transplants. Among the rest, 52 (40%) children had been on peritoneal dialysis, nine (8%) on haemodialysis and 29 (22%) had been on both. The most common primary diagnosis was congenital abnormalities of the kidney and urinary tract (CAKUT) with or without vesico-ureteric reflux (36, 28%) ( Table 3) .
Most of our RTR (73, 57%) were on dual maintenance immunosuppressive therapies with the majority on either mycophenolate mofetil (MMF) (34) or tacrolimus (21) in Table 1 . CKD comorbid conditions as per K/DOQI 1 Hypertension: SBP greater than 95th centile for age, sex and height centile. As per The Fourth US Task Force on hypertension recommendations [10] or on any anti-hypertensive medication 2 Anaemia: less than fifth centile for age and sex [14] 3 Acidosis: bicarbonate less than 22mmol/L among children >2 years of age or <20 mmol/l among <2 years of age [15] 4 Microalbuminuria: spot UAC of 2.0-20 mg/mmol (males) or 3.0-30 mg/mmol (females) [2] combination with corticosteroids. The rest were on triple maintenance immunosuppressive agents, which included a combination of corticosteroids and tacrolimus with azathioprine or MMF. The mean corticosteroid dose was 0.08 ± 0.05mg/kg/day. The mean tacrolimus dose was 0.1 ± 0.08mg/kg/day ( Table 2) .
Outcome data
The distribution of CKD stages among our RTR is shown in Table 2 . As expected, the median duration of follow-up post-transplantation was significantly longer for lower eGFR and higher stages of CKD (P = 0.01). There were no significant differences between duration of pre-transplant CKD and stages of post-transplant CKD (P = 0.4). Haematological parameters. Anaemia was present in half (65) of the study population. K/DOQI target of 11g/dl was not met among 28 (21%) children (Table 4) . Erythropoietin-stimulating agent (ESA) was used in 19 (15%) children, of whom six (32%) had Hb < 11g/dl. Eight (29%) children with Hb < 11g/dl were not on iron therapy, and among this sub-group the ferritin ranged from 8 to 458
Despite a significant increase in the use of ESA (P = 0.0001) and iron supplementation (P = 0.004) across the stages of CKD, there was a significant rise in anaemia along with failure to meet the K/DOQI cut-off of 11g/dl (P = 0.004 and P = 0.0007, respectively).
Hypertension. Overall, 68 children (53%) were hypertensive as per our definition. Incidence of uncontrolled blood pressure (SBP > 95th percentile) was significantly greater among Stage 4 (T) children, although all of them were on anti-hypertensives albeit with concerns of non-adherence in some (Table 5 ). The median number of anti-hypertensive agents per RTR varied from one in Stage 1 (T), one (range 1-2) in Stage 2 (T), one (range 1-3) in Stage 3 (T) and two (range 1-4) in Stage 4 (T) (P = 0.2). Overall, 22 (17%) children had suboptimal blood pressure control which was defined as SBP > 90th centile, and among them six (27%) were not on any anti-hypertensive medication. Micro-and macroalbuminuria. Albuminuria was assessed by early-morning spot UAC. Data were available from 126 (98%) RTR. UAC among the study population varied from 0.1 to 1023 (median 3.8) mg/mmol. Albuminuria was present in 78 (60%) children, and among them 62 (80%) had microalbuminuria. Only 15 (24%) children with microalbuminuria and six (38%) with macroalbuminuria were on angiotensin-converting enzyme inhibitors (ACEi). UAC did show a significant rise across the stages of CKD from 0-695 (median 2. Bone parameters. Corrected calcium levels adjusted for hypoalbuminaemia were found to be abnormal in 17 (13%) children and phosphate in 24 (19%) . Hyperphosphataemia did show a significant increase across the stages of CKD (P = 0.001) ( Table 6 ). Mean calcium phosphate product was 3.13 ± 0.47 mmol 2 /L 2 , and no RTR had abnormal calcium phosphate product.
Only two (13%) out of 15 children with hyperphosphataemia were on phosphate binders, although dietary advice had been given to all. There was one patient each in Stages 1 (T) and 2 (T) CKD with hyperphosphataemia; these patients were not on phosphate binders. Similarly, none of the seven children in Stage 3 (T) CKD with hyperphosphataemia were on phosphate binders, and only two of the six with hyperphosphataemia in Stage 4 (T) were on phosphate binders. Although the percentage on phosphate binder was higher in Stage 4, its use did not increase significantly across the stages. Mean alkaline phosphatase was 183 ± 89 U/L, and no significant trend could be demonstrated.
The mean PTH of the group was 5.7 ± 4.9 pmol/L, and it rose significantly from lower to higher stages of CKD (P = 0.002; Table 5 ). As per K/DOQI guideline, 36% (n = 46) had appropriate PTH for their stages of CKD, and hyperparathyroidism was most common in Stage 4 (T) (40%).
We endeavour to maintain PTH within normal range in our institution irrespective of stages of CKD, so we also analysed the PTH data according to the normal range. This showed that 79 (61%) children had normal PTH level, a greater number when compared to the assessment as per K/DOQI criteria. Despite aiming for a normal PTH with aggressive use of 1-alfacalcidol, only four (3%) children had a suppressed PTH level. A high proportion (90, 70%) of children were on 1-alfacalcidol, and its use increased significantly across the stages (P = 0.002). Acidosis. Thirty-nine (30%) children had acidosis as per the K/DOQI guideline, and among them 18 (46%) were on bicarbonate supplements. Acidosis showed a significant (P = 0.03) increase and so did use of bicarbonate (P = 0.03) ( Table 7) . Among those with acidosis, 21 (54%) children were not on bicarbonate supplement, of whom four (57%) were in Stage 2 (T), 15 (60%) in Stage 3 (T) and two (29%) in Stage 4 (T) (P = 0.33).
Growth and nutrition. Short stature was identified in 29% (37) of our study population. Height was lower among 
Discussion
Our evaluation of the largest single-centre cohort of paediatric RTR with the longest post-transplant follow-up demonstrated a high prevalence of CKD (66% Stages 3 and 4) and its related complications. In addition, it also showed that longer duration of follow-up correlated with higher stages of CKD. The trend for higher incidence of Stage 3 CKD (T) in transplants performed for CAKUT as well as for PUV needs to be examined further in future studies. Although not examined in this study, a likely explanation might be bladder dysfunction, which often persists even after post-transplantation in these conditions. This might also be the likely explanation for the higher incidence of Stage 4 CKD (T) among those transplanted for PUV or neurogenic bladder. Chronic kidney disease in paediatric renal transplantation 1317
In the original K/DOQI CKD classification, RTR were mentioned, but their inclusion was only emphasized later on in a position statement from KDIGO [1, 2] . This gained further importance with recommendation of a formal clinical action plan post KDIGO consensus conference [16] . Inclusion of RTR in the CKD classification has been proposed since acute rejection episodes, chronic allograft nephropathy with or without calcineurin nephrotoxicity and many other factors are likely to contribute to a loss of renal allograft function [17] . Implementation of this classification has its potential advantages of facilitating earlier initiation of therapeutic strategies to delay progression of renal allograft dysfunction, enhancing continuity of patient care and standardizing physician communication which should lead to greater research impetus. Despite this, CKD in non-RTR may not be identical to the CKD in RTR [18, 19] , and therefore both the relevance and the utility of the inclusion of CKD staging in RTR needs to be justified [20] . The prevalence of CKD among the RTR is likely to be important since it may be the key to the improvement of long-term renal allograft survival which has remained an elusive goal in renal transplantation [21, 22] . Despite advances, cardiovascular complications are significant factors for the overall mortality and morbidity of RTR, and chronic allograft dysfunction remains one of the leading causes of allograft failure even among paediatric RTR [22] [23] [24] . Although there are a few adult studies [3] [4] [5] [6] [7] , paediatric data simultaneously investigating all major complications of CKD at a single point of time are limited (Table 8 ) [8, 9] .
Our incidence of CKD and its related complications were similar to previous studies (Table 8) . Anaemia was the commonest observed CKD complication, but its incidence was considerably lower than previous paediatric studies [8, 9, 25] . This may be explained by the fact that we did not include use of iron supplementation and/or ESA in the definition of anaemia. If we had included the use of ESA and iron supplementation, our incidence of anaemia (87, 67%) would have been within previously reported range (65% to 80%) [8, 9, 25] . Ferritin did not show any correlation with haemoglobin, and, despite the fall in haemoglobin, ferritin increased from lower to higher stages of CKD. This to a large extent reiterates the underlying chronic inflammatory nature of CKD. Our incidence of hypertension was lower (53%) than the 70% to 80% reported by previous studies. Although some of it might be explained by our measuring only systolic blood pressure, it can also be a reflection of our strict corticosteroid weaning policy and rigorous management of hypertension among paediatric RTR [8, 9] . However, the gold standard would have been 24-h ambulatory blood pressure monitoring. Use of 1-alfacalcidol was higher than those reported by previous studies probably due to our unit's policy of normalizing PTH. This may explain our higher incidence of hypercalcaemia (10%) than hypocalcaemia (3%) in contrast to most of the other studies [5, 6] .
None of the previous paediatric studies looked at albuminuria among RTR. In our study, albuminuria was the second commonest complication after anaemia, and it showed a statistically significant increase across the stages of CKD. This is likely to have important clinical implications in view of recent evidence among adults linking micro-and macroalbuminuria with renal allograft loss even in RTR [26] .
While analysing growth failure, we only looked at short stature (height <−2 SDS) whereas Feber et al. [8] also included the use of growth hormone or high-calorie diet. Despite this difference in definition, our incidences were quite similar to Feber et al. with no statistically significant trend between growth and CKD stages. As shown by Vester et al., post-transplant height SDS does not always show a sustained improvement, and RTR may not achieve optimal final height [27] . Despite the presence of short stature in over a quarter (29%) of the study population, only one child in our study was on recombinant human growth hormone (rhGH). This may reflect the lack of formal approval by either North American or European drug regulatory agencies for the use of rhGH for growth failure in RTR as well as reported associations with post-transplant lymphoproliferative disorder and the use of rhGH during pre-transplant chronic renal insufficiency phase [28, 29] .
Few studies have looked into the incidence of obesity among paediatric RTR, and their results have been usually comparable with the prevalence of obesity in the general population [8, 27, 30] .Our incidence of obesity was considerably higher than those reported by population-based studies in both the UK [31] and the USA [32] .
Similar to previous studies (Table 8) , our study also emphasizes that CKD management is far from optimum among RTR [5, 9] . Thirty-five per cent RTR with anaemia were on neither iron nor erythropoietin, 73% with hyperphosphataemia were not on phosphate binders, and 56% of children with acidosis were not on bicarbonate supplementation. Although proteinuria was the second commonest complication, only 27% (n = 21) of the RTR were on ACEi. At the same time, these results should be interpreted keeping in mind that reasons for commencing and/or withholding medicines in clinical practice may not always be evident in retrospective data especially as clinicians wish to ensure that adherence (especially of immunosuppressive agents) is maintained in RTR. The incidence of the common complications of CKD in our transplant group was quite similar to paediatric studies on non-RTR CKD [33] . The major differences were the higher incidence of anaemia and presence of significant hypertension even in early stages of CKD in the RTR, findings which were similar to White et al. [9] .
Most of the limitations of this study are those inherent to any single-centre retrospective study. Local medical practice and changes in immunosuppressive agents over the last decade may have influenced some of the outcome parameters. Utilization of CKD medication was looked at a given point of time, and we may have missed subsequent actions initiated as a result of abnormal findings. We also did not look at adherence which is always a major issue among RTR and could partly explain the high incidence of CKD complications. Formal measurement of GFR would have been more accurate, but the primary purpose of the study was to look at the relevance of K/DOQI guideline, and hence we chose eGFR as per K/DOQI recommendations. In calculating the eGFR, we used 'k' 1318 R. Sinha et al.
which was validated in our hospital on a group of CKD children but not specifically among renal transplants. Estimated GFR was expressed as discrete variable instead of continuous; but this was required to answer our basic question regarding utility of K/DOQI CKD classification in RTR. We also chose not to consider those on treatment but with normal parameters as abnormal since there is no mention for their inclusion in K/DOQI guidelines. Lastly, it can be argued that ideally we should also have looked into dyslipidaemia, but although we do monitor fasting lipid levels, the evidences regarding utility of early intervention for dyslipidaemia with statins are marginal among adult RTR and virtually unexplored in paediatric RTR [34, 35] . Despite these shortcomings the study does have its strength. It is the largest paediatric study to date and examined all of the CKD parameters (except lipid profile) strictly as per K/DOQI guideline. Importantly, our data collection was almost complete, as apart from lack of UAC data from three RTR we did not miss any other relevant data.
The majority of prospective studies in transplantation continue to be dominated by immunosuppressive trials [36] , although non-immune factors might also be important in the improvement of long-term renal allograft survival. Fortunately, most of the CKD comorbidity factors are to some extent modifiable [37] . Although the role of anaemia in progressive renal allograft decline has not been clearly established, a prospective study did show that erythropoietin therapy slows the rate of allograft decline [38] . Similarly, proteinuria has also been associated with both renal allograft and patient survival [25, 39] , and the use of ACEi or angiotensinogen receptor blocker (ARB) has been shown to be effective in decreasing urinary protein excretion without loss of GFR among RTR [40, 41] . There are observational studies in both adult and paediatric practice which have demonstrated an association of hypertension with renal allograft failure [42] [43] [44] . Hyperphosphataemia has been linked to cardiovascular morbidity and mortality among CKD, and the findings of a number of RTR not being adequately treated are quite concerning. Likewise, a similar lack of treatment was evident for metabolic acidosis, although it has been shown to contribute to linear growth failure and renal osteodystrophy [15] .
In conclusion, the present study utilizing K/DOQI criteria did identify a major proportion of paediatric RTR in advanced stages of CKD with a sizeable number of them being under-treated, but despite this a number of questions regarding its routine use remains unanswered. Similar to other studies, we also found certain unique differences between RTR CKD and non-RTR CKD, such as higher prevalence of anaemia and presence of significant hypertension even at early stages of CKD (T) [9, 18, 19] . RTR have theoretically lower risk of under-recognition and under-treatment as they are already under nephrology care, and hence the utility of five stages among RTR have been questioned particularly as most of the RTR CKD tends to be in Stage 3 [20] . Studies have demonstrated plasma creatinine to be a poor predictor of renal allograft loss [45] , whereas the K/ DOQI classification is based on eGFR derived from creatinine. Future prospective studies should aim to answer these questions as the inclusion of RTR in CKD classification would be only relevant if this can be shown to result in prevention, early detection and treatment of CKD-related complications which should thereafter be shown to slow the rate of decline of allograft function.
